Portal de Periódicos da CAPES

Recent advances in myorelaxant therapy

2001; Wiley; Volume: 11; Issue: 5 Linguagem: Inglês

10.1046/j.1460-9592.2001.00661.x

1460-9592

G. MEAKIN,

Anesthesia and Pain Management

Pediatric AnesthesiaVolume 11, Issue 5 p. 523-531 Recent advances in myorelaxant therapy George H. Meakin MB, CHB, MD, FRCA, George H. Meakin MB, CHB, MD, FRCA University Department of Anaesthesia, Royal Manchester Children's Hospital, Pendlebury, Manchester, UKSearch for more papers by this author George H. Meakin MB, CHB, MD, FRCA, George H. Meakin MB, CHB, MD, FRCA University Department of Anaesthesia, Royal Manchester Children's Hospital, Pendlebury, Manchester, UKSearch for more papers by this author First published: 21 December 2001 https://doi.org/10.1046/j.1460-9592.2001.00661.xCitations: 11 George H. Meakin, University Department of Anaesthesia, Royal Manchester Children's Hospital, Pendlebury, Manchester M27 4HA, UK. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Griffiths HR & Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942; 3 : 418–420. 2 Baird WLM & Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide: a pilot study in a man. Br J Anaesth 1967; 39 : 775–780. 3 Savarese JJ & Kitz RJ. Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 1975; 42 : 236–239. 4 Mirakhur RK. Newer neuromuscular blocking drugs: an overview of their clinical pharmacology and therapeutic use. Drugs 1992; 44 : 182–199. 5 Bedford RF. From the FDA. Anesthesiology 1995; 82 : 33A–33A. 6 Bowman WC, Rodger IW, Houston J et al. Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988; 69 : 57–62. 7 Wierda JMKH & Proost JH. Structure-onset relationship of steroidal neuromuscular blocking agents. In: Fukushima K, Ochiai R, eds. Muscle Relaxants: Physiologic and Pharmacologic Aspects. Tokyo: Springer; 1995: 163–166. 8 Proost JH, Wierda JMKH, Meijer DKF. Structure-pharmacokinetic and pharmacodynamic relationships of steroidal neuromuscular blocking drugs. In: Fukushima K, Ochiai R, eds. Muscle Relaxants: Physiologic and Pharmacologic Aspects. Tokyo: Springer; 1995: 205–212. 9 Wierda JMKH, Beaufort AM, Kleef UW et al. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can J Anaesth 1994; 41 : 213–220. 10 Wierda JMKH, Kleef UW, Lambalk LM et al. The pharmacodynamics and pharmacokinetics of ORG 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991; 38 : 430–435. 11 Wierda JMKH, De Wit APM, Kuizenga K et al. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. Br J Anaesth 1990; 64 : 521–523. 12 Sugai N & Yajima C. Pharmacokinetics and pharmacodynamics of aminosteroidal neuromuscular blocking agents and their metabolites. In: Fukushima K, Ochiai R, eds. Muscle Relaxants: Physiologic and Pharmacologic Aspects. Tokyo: Springer; 1995. 13 Woefel SK, Brandon BW, Cook DR et al. Effects of bolus administration of ORG-9426 in children during nitrous oxide-halothane anesthesia. Anesthesiology 1992; 76 : 939–942. 14 Bikhazi G, Marin F, Halliday NJ et al. The pharmacodynamics of rocuronium in pediatric patients anesthetized with halothane. J Anesth 1994; 8 : 256–260. 15 Meretoja OA, Taivainen T, Erkola O et al. Dose–response and time-course of effect of rocuronium bromide in paediatric patients. Eur J Anaesthesiol 1995; 12 : 19–22. 16 Hopkinson JM, Meakin G, McCluskey A et al. Dose–response relationship and effective time to satisfactory intubation conditions after rocuronium in children. Anaesthesia 1997; 52 : 428–432. 17 Woelfel SK, Brandon BW, McGowan FX et al. Neuromuscular effects of 600 mg·kg–1 of rocuronium in infants during nitrous oxide-halothane anaesthesia. Paed Anaesth 1994; 4 : 173–177. 18 Cooper R, Mirakhur RK, Clarke RSJ et al. Comparison of intubating conditions after administration of ORG 9426 (rocuronium) and suxamethonium. Br J Anaesth 1992; 69 : 269–273. 19 Puhringer FK, Khuenl-Brady KS, Koller J et al. Evaluation of the endotracheal intubating conditions of rocuronium (ORG 9426) and succinylcholine in outpatient surgery. Anesth Analg 1992; 75 : 37–40. 20 Huizinga RHG, Vandenbrom RHG, Wierda JMKH et al. Intubating conditions and onset of neuromuscular block of rocuronium (Org 9426): a comparison with suxamethonium. Acta Anaesthesiol Scand 1992; 36 : 463–468. 21 Fuchs-Buder T & Tassonyi E. Intubating conditions and time course of rocuronium-induced neuromuscular block in children. Br J Anaesth 1996; 77 : 335–338. 22 Naguib M, Samarkandi AH, Ammar A et al. Comparison of suxamethonium and different combinations of rocuronium and mivacurium for rapid tracheal intubation in children. Br J Anaesth 1997; 79 : 450–455. 23 Stoddart PA & Mather SJ. Onset of neuromuscular blockade and intubating conditions one minute after the administration of rocuronium in children. Paed Anaesth 1998; 8 : 37–40. 24 Dobson AP, McCluskey A, Meakin G et al. Effective time to satisfactory intubation conditions after administration of rocuronium in adults: comparison of propofol and thiopentone for rapid sequence induction. Anaesthesia 1999; 54 : 172–197.DOI: 10.1046/j.1365-2044.1999.00655.x 25 Lowry DW, Carroll MT, Mirakhur RK et al. Comparison of sevoflurane and propofol with rocuronium for modified rapid-sequence induction of anaesthesia. Anaesthesia 1999; 54 : 247–252.DOI: 10.1046/j.1365-2044.1999.00745.x 26 McCourt KC, Samela L, Mirakhur RK et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. Anaesthesia 1998; 53 : 867–871. 27 Motsch J, Leuwer M, Bottiger BW et al. Dose–response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia. Eur J Anaesthesiol 1995; 12 : 73–78. 28 Van Den Broek L, Wierda JMKH, Smeulers NJ et al. Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994; 73 : 331–335. 29 Wright PMC, Brown R, Lau M et al. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology 1999; 90 : 16–23. 30 Brandom BW, Bikhazi G, Ginsberg B et al. Org 9487 in neonates and infants anaesthetized with nitrous oxide-halothane. Eur J Anaesthesiol 1997; 14 : 33–34. 31 Brandom BW, Bikhazi G, Ginsberg B et al. Org 9487 or mivacurium in children anaesthetized with nitrous oxide-halothane. Eur J Anaesthesiol 1997; 14 : 34–35. 32 Kahwaji R, Bevan DR, Bikhazi G et al. Dose-ranging study in younger adults and elderly patients of ORG 9487, a new, rapid onset, short duration muscle relaxant. Anesth Analg 1997; 84 : 1011–1018. 33 Meakin GH, Meretoja OA, Motsch J et al. A dose-ranging study of rapacuronium in pediatric patients. Anesthesiology 2000; 92 : 1002–1009. 34 Sparr HJ, Mellinghoff H, Blobner M et al. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients. Br J Anaesth 1999; 82 : 537–541. 35 Hayes A, Breslin D, Reid J et al. Rapacuronium (Org 9487) for use during rapid sequence induction of anaesthesia: comparison with succinylcholine. Br J Anaesth 1999; 83 : 179P–179P. 36 Ali HH & Savarese JJ. Monitoring of neuromuscular function. Anesthesiology 1976; 45 : 216–249. 37 Mills KG, Scott JM, Parker CJR et al. Pharmacodynamics of Org 9487: onset and recovery characteristics of single and three incremental bolus doses. Br J Anaesth 1996; 77 : 684–685. 38 Goulden MR & Hunter JM. Rocuronium (Org 9487): do we have a replacement for succinylcholine? Anaesthesia 1999; 82 : 489–492. 39 Blobner M, Mirakhur RK, Wierda JMKH et al. Rapacuronium 2.0 or 2.5 mg·kg−1 for rapid sequence induction: comparison with succinylcholine 1.0 mg·kg−1. Br J Anaesth 2000; 85 : 724–731. 40 Meakin GH, Pronske EH, Lerman J et al. Bronchospasm after rapacuronium in infants and children. Anesthesiology 2001; 94 : 926–927. 41 Goudsouzian NG. Rapacuronium and bronchospasm. Anesthesiology 2001; 94 : 727–728. 42 Kron SS. Severe bronchospasm and desaturation in a child associated with rapacuronium. Anesthesiology 2001; 94 : 923–924. 43 Naguib M. How serious is the bronchospasm induced by rapacuronium? Anesthesiology 2001; 94 : 924–925. 44 Cook DR, Stiller RL, Weakly JN et al. In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine. Anesth Analg 1989; 68 : 452–456. 45 Saverese JJ, Ali HH, Basta SJ et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). Anesthesiology 1988; 68 : 723–732. 46 Sarner JB, Brandom BW, Woelfel SK et al. Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia. Anesth Analg 1989; 68 : 116–121. 47 Cook DR, Wingard LB, Taylor FH. Clinical pharmacology of succinylcholine in infants, children and adults. Clin Pharmacol Ther 1976; 20 : 493–498. 48 Brandom BW, Stiller RL, Cook DR et al. Pharmacokinetics of atracurium in anaesthetised infants and children. Br J Anaesth 1986; 58 : 1210–1213. 49 Goudsouzian NG, Alifimoff JK, Eberly C et al. Neuromuscular and cardiovascular effects of mivacurium in children. Anesthesiology 1989; 70 : 237–242. 50 McCluskey A & Meakin G. Dose–response and mimimum time to satisfactory intubation conditions after mivacurium in children. Anaesthesia 1996; 51 : 438–441. 51 Goudsouzian NG, Denman W, Schwartz A et al. Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide. Anesthesiology 1993; 79 : 919–925. 52 From RP, Pearson KS, Choi WW et al. Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia. Br J Anaesth 1990; 64 : 193–198. 53 Shanks CA, Fragen RJ, Pemberton D et al. Mivacurium-induced neuromuscular blockade following single bolus doses and with continuous infusion during either balanced or enflurane anesthesia. Anesthesiology 1989; 71 : 362–366. 54 Maddenini VR & Mirakhur RK. Prolonged neuromuscular block following mivacurium. Anesthesiology 1993; 78 : 1181–1184. 55 Meretoja OA, Taivainen T, Wirtavuori K. Pharmacodynamics of mivacurium in infants. Br J Anaesth 1994; 73 : 490–493. 56 Meretoja OA & Olkkola KT. Pharmacodynamics of mivacurium in children using a computer-controlled infusion. Br J Anaesth 1993; 71 : 232–237. 57 Alifimoff JK & Goudsouzian NG. Continuous infusion of mivacurium in children. Br J Anaesth 1989; 63 : 520–524. 58 Maddenini VR, Mirakhur RK, McCoy EP et al. Neuromuscular effects and intubating conditions following mivacurium: a comparison with suxamethonium. Anaesthesia 1993; 48 : 940–945. 59 Woefel SK, Brandom BW, McGowan FX et al. Clinical pharmacology of mivacurium in pediatric patients less than two years old during nitrous oxide-halothane anesthesia. Anesth Analg 1993; 77 : 713–720. 60 Stenlake JB, Waigh RD, Urwin J et al. Atracurium: conception and inception. Br J Anaesth 1983; 55 : 3S–10S. 61 Chapple DJ, Miller AA, Ward JB et al. Cardiovascular and neurological effects of laudanosine. Br J Anaesth 1987; 59 : 218–225. 62 Ward S, Boheimer N, Weatherley BC et al. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. Br J Anaesth 1987; 59 : 697–706. 63 Yate PM, Flynn PJ, Arnold RW et al. Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive care unit. Br J Anaesth 1987; 59 : 211–217. 64 Lien CA, Schmith VD, Belmont MR et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/ opioid/barbiturate anesthesia. Anesthesiology 1996; 84 : 300–308. 65 Lien CA, Schmith VD, Belmont MR et al. Pharmacokinetics/dynamics of 51W89 in healthy patients during opioid anesthesia. Anesthesiology 1994; 81 : A1082–A1082. 66 Ward S, Neill EAM, Weatherley BC et al. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). Br J Anaesth 1983; 55 : 113–118. 67 Meretoja OA, Taivainen T, Wirtavuori K. Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. Br J Anaesth 1995; 74 : 6–11. 68 Brandom BW, Rudd GD, Cook DR. Clinical pharmacology of atracurium in paediatric patients. Br J Anaesth 1983; 55 : 117S–121S. 69 Belmont MR, Lien CA, Quessy S et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82 : 1139–1145. 70 Basta SJ, Ali HH, Savarese JJ et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg 1982; 61 : 723–729. 71 Littlejohn IH, Abhay K, El Sayed A et al. Intubating conditions following 1R CIS, 1′R CIS atracurium (51W89): a comparison with atracurium. Anaesthesia 1995; 50 : 499–502. 72 Waite I, Meakin G, Meretoja OA et al. Endotracheal intubation conditions after cisatracurium in infants and children. Br J Anaesth 1998; 80 : 139–140. 73 Meretoja OA, Taivainen T, Wirtavuori K. Cisatracurium during halothane and balanced anaesthesia in children. Paed Anaesth 1996; 6 : 373–378. 74 Lien CA, Belmont RA, Abalos A et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82 : 1131–1138. 75 Miller RD. Is 51W89 an improvement compared with atracurium? Br J Anaesth 1995; 74 : 1–2. Citing Literature Volume11, Issue5September 2001Pages 523-531 ReferencesRelatedInformation